A Phase 1 clinical study with TTX-MC138
Latest Information Update: 15 Dec 2023
At a glance
- Drugs TTX-MC138 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Pharmacokinetics
- Sponsors TransCode Therapeutics
- 15 Dec 2023 New trial record
- 12 Dec 2023 According to TransCode Therapeutics media release, company will enter Phase I clinical testing in 2024.